Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Firefly Neuroscience Inc Market Cap
The Firefly Neuroscience Inc (AIFF) share price is expected to decrease by 100% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered AIFF. Price targets range from $ at the low end to $ at the high end. The current analyst consensus for AIFF is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned AIFF 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Firefly Neuroscience Inc to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on AIFF. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of AIFF.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
Data Not Found! | ||||
When did it IPO
2024
Staff Count
42
Country
Canada
Sector/Industry
Technology/Software - Application
CEO
Mr. Jon Olsen
Market Cap
$26.1M
In 2023, AIFF generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that AIFF's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 14 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Firefly Neuroscience, Inc. (NASDAQ: AIFF) has listed on Nasdaq and partnered with neuroscience firms to enhance brain health solutions. They reported Q3 financial results on Nov. 14, 2024.
Why It Matters - Firefly's Nasdaq listing and partnerships with neuroscience firms signal growth potential and innovation in brain health, making it a notable opportunity for investors in biotech and AI sectors.
Wed, 06 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Firefly Neuroscience, Inc. (NASDAQ: AIFF) will attend the Capital Event Management Conference in Miami from November 22-24, 2024, focusing on AI solutions for brain health.
Why It Matters - Firefly Neuroscience's participation in a major conference could enhance visibility, attract investment, and signal confidence in its AI-driven solutions for neurological disorders, potentially impacting stock performance.
Fri, 25 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Firefly Neuroscience granted 557,885 restricted shares to Executive Chairman David Johnson as an inducement under his employment agreement, in compliance with Nasdaq rules.
Why It Matters - The grant of restricted shares to the Executive Chairman signals confidence in leadership and aligns management interests with shareholder value, potentially impacting stock performance and investor sentiment.
Wed, 16 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Firefly conducted a Phase 1 study using EEG headsets from partner Zeto, with data analyzed through Firefly's AI BNA technology platform.
Why It Matters - Partnerships and advancements in AI technology can enhance product offerings and market position, potentially leading to increased revenue and investor interest in Firefly.
Fri, 11 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Firefly Neuroscience, Inc. (NASDAQ: AIFF) will participate in several investor conferences in October 2024, focusing on AI solutions for neurological and mental health disorders.
Why It Matters - Firefly Neuroscience's participation in investor conferences signals engagement with the investment community, potentially boosting visibility and attracting interest in its AI-driven healthcare innovations.
Tue, 10 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Firefly is expanding its FDA-cleared BNA™ technology to additional hospitals and physician offices through a new partnership.
Why It Matters - The partnership signals growth potential for Firefly's FDA-cleared technology, likely boosting revenue and market presence, which can positively impact stock performance and investor confidence.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
